Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.
McNamee
P
P
University of Newcastle-upon-Tyne.
van Doorslaer
E
E
Segaar
R
R
D000743:Anemia, Hemolytic / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D001803:Blood Transfusion / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin